Background. Care of patients with locally recurrent rectal cancer (LRRC) requires careful patient selection. While curative resection offers survival benefits, significant tradeoffs exist for the patient. Knowledge of patient-reported outcomes will help inform treatment decisions. Methods. Quality of life (QOL) and pain were prospectively assessed in 105 patients treated for LRRC at a single institution, using the validated Functional Assessment of Cancer Therapy-Colorectal (FACT-C) and Brief Pain Inventory (BPI) questionnaires. In 54 patients enrolled and followed from diagnosis of LRRC, relationship between pretreatment pain, QOL, and overall survival (OS) were examined. Results. Patients underwent curative surgical resection (C, 59%), noncurative surgery (NC, 12%) or nonsurgical treatment (NS, 28%). Median OS was 7.1, 1.4, and 1.9 years, respectively (C versus NC: p \ 0.001; C versus NS: p = 0.006; NC versus NS: p = 0.261). Physical wellbeing QOL differed over time (p = 0.042), with greatest difference between C and NC surgery patients (p = 0.049). The remaining QOL domain scores and pain scores demonstrated no significant time or treatment effect. For the 54 patients assessed from diagnosis, median OS was independently predicted by treatment group (C, NC, NS: 4.3, 1.7, versus 2.4 years; p \ 0.001) and pretreatment pain intensity (score B 4 versus [ 4: 3.8 versus 2.0 years; p = 0.001).
Conclusion. Curative surgery offered prolonged survival, but significant pain exists among long-term survivors and should be a focus of survivorship care. Noncurative surgery did not offer apparent advantages over nonsurgical palliation. Patient's pretreatment pain has prognostic value, and should be assessed, treated, and considered in treatment decisions.
Recent advances in multimodality therapy and wide acceptance of total mesorectal excision (TME) have significantly improved the care of patients with rectal cancer. 1, 2 Rates of local pelvic failure after primary curative therapy have declined from 20-30%, to only 6-11% in the setting of clinical trials and specialized centers. 3, 4 However, locally recurrent rectal cancer (LRRC) remains a challenging problem. Local pelvic failure not only shortens patient life expectancy but also decreases their quality of life (QOL). 5 Common cancer-related morbidities include severe pelvic pain, bleeding, obstruction, fistula, and chronic pelvic sepsis. 6 While expected median survival is often measured in months with supportive care alone, treatment options are often limited by previous pelvic irradiation, surgery, and/or systemic therapy. 7, 8 Indeed, care for patients with LRRC requires careful consideration of both patient-and tumorrelated factors in deciding which patients are suitable candidates for curative resection, surgical palliation or nonsurgical treatments.
Current literature regarding LRRC has been dominated by reported outcomes of surgical salvage with curative intent. In these highly selected patients, a survival advantage has been demonstrated after margin-negative resection, with reported 5-year overall survival (OS) rates of 9-43%. 3, 9 However, significant trade-offs exist. Perioperative morbidity and mortality are substantial; bowel, urinary, and sexual functions as well as lifestyle can be permanently altered; and prolonged multidimensional rehabilitation is needed after hospital discharge. 10 Although survival rates and short-term morbidities have been described, little is known about patient-reported outcomes such as functional lifestyles, symptoms, and QOL. Furthermore, outcomes of patients who undergo noncurative surgery or nonsurgical treatment have not been well investigated. Filling these gaps in knowledge would more fully inform the surgeon and the patient when challenged with these difficult treatment decisions. Therefore, a single-institutional prospective survey study of patients treated for LRRC was conducted with the following aims: (1) compare the overall survival (OS) of patients undergoing curative surgery (C), noncurative or palliative surgery (NC) or nonsurgical treatments (NS); (2) measure the QOL and pain symptoms over time in patients undergoing different interventions; and (3) explore the relationship between baseline QOL and pain symptoms with OS.
METHODS

Study Cohort and Outcome Measures
After approval from the Institutional Review Board, 105 eligible and consenting adult patients (C18 years of age) with LRRC were prospectively enrolled to the study protocol between August 1997 and March 2007. LRRC was defined as histologically proven recurrent rectal adenocarcinoma in the pelvis, at least 3 months after completion of primary curative therapy. Patients were limited to those with command of the English language for survey research, not having pre-existing chronic pain syndrome or constipation, and agreeing to survey completion. In this study, patients who underwent surgical exploration with complete resection of gross tumor were considered to have had curative resection (C); those who underwent noncurative exploration with residual gross tumor, either because of unexpected intraoperative findings or because of intent to palliate symptoms only, were considered to have had noncurative or palliative resection (NC); and the remainder did not have surgical intervention (NS).
Patients were enrolled to the study protocol at various time points after diagnosis of LRRC. A subgroup of 54 patients was enrolled prior to treatment initiation, while the remainder were enrolled after treatment for their LRRC had initiated. Patients reported the medical intervention for pain that they were receiving at time of study enrollment, while subsequent pain management was at the discretion of the treating physicians and referral to specialist pain service was made as needed. Quality of life and pain symptoms were surveyed by self-administered questionnaires at enrollment and then every 3 months, until death or last follow-up. Treating physicians were blinded to survey results.
Instruments for QOL and Pain Assessment
The Functional Assessment of Cancer Therapy-Colorectal (FACT-C) is a disease-specific self-report QOL instrument and a part of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement Quality of Life System. 11, 12 FACT-C contains four domains and the colorectal subscale (CCS). According to the instrument, patients were instructed to answer based on their experience over the past 7 days. The physical well-being domain (PWB) addressed energy, nausea, family needs, pain, treatment toxicity, sickness feeling, and time in bed; the social well-being domain (SWB) addressed distance from friends, emotional support, general support, illness acceptance, family communication, partner relationship, and sexual satisfaction; the emotional well-being domain (EWB) addressed sadness, self-pride, hope, nervousness, and worry about death; and the functional well-being domain (FWB) addressed work, life enjoyment, illness acceptance, sleep, leisure, and overall contentment with QOL. The CCS elicited symptoms of abdominal cramping, weight loss, bowel control, digestion, diarrhea, appetite, and body image. Each item was scored from 0 (not at all) to 4 (very much). The maximal possible scores of PWB, SWB, EWB, FWB, and CCS are 28, 28, 20, 28, and 28 (version 2.0), while FACT-C is a summation of these scores (maximum 132). Higher score denotes better QOL. Internal consistency, reliability, and concurrent validity of FACT-C have been demonstrated. It can discriminate between patient groups of different functional status and disease extent, and is sensitive to change over time. 12 The Brief Pain Inventory (BPI)-short form is one of the most widely used measurement tools for assessing clinical pain. 13, 14 According to a recent consensus panel, key measures of pain are pain intensity (severity) and pain interference (impact of pain on functioning). 15, 16 The pain intensity score is the average of the ''worst,'' ''least,'' ''average,'' and ''now'' pain scores on a scale from 0 (no pain) to 10 (pain as bad as you can imagine). The pain interference score is the average of the interference scores given to seven daily activities (i.e., general activity, walking, work, mood, enjoyment of life, relations with others, and sleep) on a scale from 0 (does not interfere) to 10 (completely interferes). The BPI has been extensively validated, and its internal consistency, reliability, and sensitivity to change have been proven. 13, 14, 17 
Statistical Analysis
The distribution of continuous variables was summarized by median and interquartile range (IQR), while that of categorical variable as frequency and percentage (%). Overall survival (OS), defined as time from date of LRRC diagnosis to date of death from any cause, was estimated by Kaplan-Meier method, censoring patients who were alive at last follow-up. Difference in OS by treatment group was compared using log-rank test. QOL and pain scores were calculated according to standard guidelines. 17, 18 To assess changes over time by different treatments, linear mixed-effect models were constructed after adjusting for treatment group and after accounting for repeated measures. Fixed effects considered were treatment, time, and interaction between time and treatment. When an overall linear trend over time was observed, interaction between time and treatment was examined by comparing different estimates of slope over time. Estimates of intercept and slope over time were compared between treatment groups using t-test, after adjusting p-values for multiple pairwise comparisons (Bonferroni method for p-value of 0.017). To explore the relationship between baseline QOL or pain score and OS, a Cox proportionalhazard regression model was constructed. In multivariate analysis, nonsignificant variables from univariate analyses were eliminated in a step-down fashion using a cutoff p value of 0.10. p Value of 0.05 denoted statistical significance unless otherwise noted. All analyses were performed using SAS version 9.1 (Cary, NC).
RESULTS
Clinical Outcomes
Curative surgical resection (C) was undertaken in 62 (59%) patients, while 13 (12.4%) and 30 (28.5%) patients underwent NC and NS treatments, respectively. Curative surgical resection procedures included: repeat rectal resection (low anterior resection, coloanal anastomosis or abdominoperineal resection) in 21 patients (33.9%), multivisceral resection with bone resection in 25 patients (40.3%), without bone resection in 9 (14.5%), and extrarectal pelvic tumor excision in 7 (11.3%). Noncurative surgery included exploratory laparotomy with biopsy of extrapelvic disease in six patients, intestinal bypass or diversion in five patients, transanal local excision in one patient, and segmental resection for contained perforation in one patient. Nonsurgical management included chemoradiation in 21 patients, brachytherapy in 2 patients, and no intervention in the remainder. The median age of the study cohort was 51 years (IQR 59-67 years), and the gender distribution was nearly equal (female: 53 patients, 50.3%). Patients did not significantly differ in age (p = 0.08) or gender (p = 0.64) across treatment groups. Chemoradiation was given as a component of overall multimodality salvage treatment in 81.8, 88.9, and 91.3% of patients in the C, NC, and NS groups (p = 0.21). From diagnosis of LRRC, median OS after C was significantly longer than that after NC or NS: 7.1 years versus 1.4 or 1.9 years, respectively (C versus NC: p \ 0.001; C versus NS: p = 0.006; NC versus NS: p = 0.261; Fig. 1 ).
Quality of Life and Pain in Different Treatment Groups over Time
Among patient-reported QOL scores, only scores in the PWB domain exhibited significant impact of treatment, time, and their interaction, as assessed by the mixed-effects model (Table 1) . To examine closely how time trends differed by treatment group, the slopes of the decline in QOL over time were compared among treatment groups (Fig. 2) . While PWB was largely preserved over time after C, it rapidly declined after NC or NS, reaching borderline significance when C and NC were compared (p = 0.049, Fig. 2 ).
Reported pain intensity and pain interference did not demonstrate significant differences among treatment groups (pain intensity: p = 0.16; pain interference: p = 0.20), over time (p = 0.25 and p = 0.29, respectively) or by their interaction (p = 0.67 and p = 0.75, respectively; Fig. 3a, b) . Patient-reported treatments for pain did not differ by treatment group (p = 0.75): use of schedule II or III narcotics was reported by 41.7, 47.6, and 46.1% of C, NC, and NS, patients, respectively; and over-the-counter medications were taken by 15, 14.3, and 7.8% of C, NC, and NS patients, respectively. Patients in different treatment groups did not differ in baseline reported pain symptoms; however, moderately high scores were reported even by long-term survivors without disease recurrence (Fig. 3a, b) . No significant impact of treatment, time or treatment 9 time interaction seen in other subdomains: social well-being (SWB), emotional well-being (EWB), functional well-being (FWB), colorectal subscale (CCS) (data not shown)
Prognostic Factors for OS
A subgroup of 54 patients were initially surveyed prior to any treatment intervention and then followed over time. In these patients, OS was not significantly associated with age, gender or baseline QOL (FACT-C score) on univariate analysis. However, both treatment group and pain intensity score significantly impacted OS. One unit higher level of pain intensity was associated with an 18% higher relative risk of dying from any cause ( Table 2 ). Both of these variables remained independent predictors of OS on multivariate analysis (Table 2) . Patients reporting pain intensity score B4 at baseline enjoyed significantly longer median OS when compared with those reporting high pain intensity score: 3.8 versus 2.0 years (p = 0.001; Fig. 4 ).
DISCUSSION
Traditionally, survival has been the primary efficacy measure of cancer treatments, and the main consideration in making treatment decisions. In the case of LRRC, however, survival gain must be considered in the context of the significant trade-offs experienced by patients during and after treatment. To our knowledge, this is the first prospective assessment of patient-reported outcomes associated with both curative and noncurative treatments for LRRC. Utilizing validated instruments and longitudinal analysis, we found that curative surgery maintained QOL and PWB over the longest survival duration, while noncurative surgery and nonsurgical treatment were both associated with declines in PWB over shorter survival periods. Furthermore, pretreatment pain score was an independent prognostic indicator of long-term OS, and pain may be common during and after treatments. Taken together, these findings identify pain as a focus for care of patients with LRRC, and help inform both the surgeon and the patient when challenged to balance survival benefit with treatment sequelae.
Curative surgical resection led to significantly longer median OS (7.1 years) from diagnosis of LRRC when compared with other treatments (1.4 years for NC surgery and 1.9 years for nonsurgical palliation). These findings are consistent with those of Hahnloser et al., who compared median OS of patients undergoing curative versus noncurative resection and reported a significant difference of 3.7 versus 2.0 years from date of surgery (p \ 0.001). 19 Another series of 105 patients treated between 1997 and 1999 demonstrated median OS of 3.9 versus 1.1 years from date of surgery, respectively (p \ 0.001). 20 The prospective nature of our protocol and the long length of follow-up available among our surviving patients allowed us to demonstrate the durability of the survival gain. Because previous literature has established that survival benefit requires radical resection of pelvic recurrent tumor to negative margins, our observed median OS of 7.1 years reflects the highly selected nature of this patient cohort. 3, 9, 19, [21] [22] [23] [24] Indeed, curative resection is typically feasible in only 20-30% of all patients with LRRC. 3 Unique in our study, we demonstrated that, in parallel to the observed differences in OS, the QOL scores from the PWB domain diverged after patients received different treatments: PWB was durably maintained over time after curative surgery but declined after noncurative treatments. Therefore, when curative resection can be achieved, patients may expect durable gains in overall survival and maintenance of physical well-being and QOL.
However, the majority of patients with LRRC are precluded from curative resection, by extensive pelvic disease, extrapelvic metastases or patient choice. Indeed, a recent population-based series found that 60% of patients with LRRC were treated by either noncurative surgery (26%) or palliative chemoradiation (34%). 8 We observed median OS of 1.4 and 1.9 years in patients undergoing noncurative surgery and nonsurgical interventions, respectively (p = 0.26). These figures largely corroborate those reported in other series and reflect the reported efficacy of modern systemic therapy for patients with stage IV colorectal cancer. 3, 8, 19, 20 Although quality rather than length of life may be the primary concern among these patients, no comparative QOL data had been available in the literature. We detected no significant differences in OS, QOL scores or pain symptom scores at any time point, between patients undergoing noncurative surgery or palliative treatments. These findings further support our previous observation that median quality-adjusted survival did not differ between patients treated with nontherapeutic surgery versus nonoperatively: 0.81 versus 1.01 quality-adjusted life years. 25 However, when healthcare costs were considered, nontherapeutic surgery was far less cost-effective than nonoperative treatments: US $45,647 versus US $19,283 (p \ 0.005). 25 Taken together, these results suggest that noncurative surgery offers no distinct advantages over nonsurgical treatments. Thus, LRRC patients are likely best cared for by a multidisciplinary team where nonsurgical treatment options are maximally considered. In addition, the undertaking of noncurative surgery should be selective and goal-directed. While intestinal bypass or diversion may palliative some patients, abdominal exploration that leaves gross residual tumor likely benefits few. The incidence of nontherapeutic laparotomy has been reported to be as high as 23%, and it may be reduced by optimal preoperative tumor imaging using high-resolution pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET), and by judicious assessment of what can realistically be accomplished intraoperatively based on surgical experience. Pain is one of the most common presenting symptoms among patients with LRRC, and was specifically assessed by a validated instrument in this study. QOL and pain scores collected prior to treatment provided a unique opportunity to investigate the prognostic value of these baseline patient-reported outcomes. Several investigators had demonstrated that baseline QOL can help predict OS in cancer patients, including those with pelvic tumors of prostatic or gynecologic origin. [26] [27] [28] [29] [30] [31] [32] In our study, intensity of pain was an independent prognostic indicator of OS, after controlling for demographic and other clinical variables, with significantly shorter median OS observed for patients rating pain greater than 4 out of 10 (3.8 versus 2.0; p = 0.001). One previous study had found that median OS among patients who presented with pain symptoms was significantly shorter than others: 2.1 years, compared with 2.6 years for patients with non-pain symptoms and 3.3 years for those who were asymptomatic (p \ 0.001). However, the pain symptom was not formally rated and was not evaluated as an independent variable in multivariate analysis. 19 One may speculate that greater pain reflects more advanced pelvic disease and thus worse OS. Because increasing pain is associated with worse QOL, greater pain may reflect poor psychosocial adaptation to their disease and worse QOL, which may in turn factor into poorer overall outcome. 33 Besides the intensity of pain, our data also revealed the long duration of pain experienced by surviving patients. Factors that predispose to chronic pain in surgical patients had been identified to include: preexisting pain, repeat surgery, psychological vulnerability, radiation, chemotherapy, and depression and anxiety. 34 Taken together, we identify disease-and treatment-related pain as a significant symptom among patients with LRRC. Detailed knowledge and assessment of pain over time represents a first step toward providing optimal medical, psychosocial, and multidisciplinary interventions to treat pain. The prognostic importance of pain underscores the critical importance of such interventions.
While the current study represents the largest prospective longitudinal assessment of QOL and pain in patients with LRRC, it is not without limitations. The cohort size remains relatively small after considering the different treatment groups. This precluded meaningful comparisons between treatment groups among the subgroup of patients followed from before treatment initiation. The absence of significant differences in other domains of QOL may also be partially accounted for by our cohort size. Alternatively, it may reflect biases inherent in the patient population collected in our study: patients with LRRC who are well enough to travel to a tertiary referral center likely enjoy or at least have adapted to adequate levels of emotional, social, and functional well-being. However, the significant differences that could be identified in PWB despite our cohort size signify the magnitude and clinical relevance of our findings.
In conclusion, although durable survival and quality-oflife benefits can be achieved among patients with LRRC, careful patient selection is required. These gains were only realized in patients suitable for curative resection, as noncurative surgery offered little advantage over palliative treatments. Pain should be a targeted focus of multidisciplinary survivor care in patients with LRRC. Finally, we have demonstrated that formal assessment of patientreported outcomes complement standard clinical variables in predicting survival. The disease and treatment effects known only to the patients reported herein highlight the limitations of assessing clinical outcomes alone in patients with LRRC and provide significant complementary value in clinical decision-making.
